Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.14)
# 3,811
Out of 5,182 analysts
313
Total ratings
26.35%
Success rate
-11.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Bodnar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRAX First Tracks Biotherapeutics | Initiates: Buy | $30 | $22.38 | +34.05% | 1 | Apr 28, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $65 → $50 | $28.16 | +77.56% | 6 | Apr 20, 2026 | |
| INKT MiNK Therapeutics | Reiterates: Buy | $35 | $11.61 | +201.46% | 15 | Apr 1, 2026 | |
| ANAB AnaptysBio | Reiterates: Buy | $66 | $66.76 | -1.14% | 15 | Mar 30, 2026 | |
| ATOS Atossa Therapeutics | Maintains: Buy | $7 → $25 | $5.33 | +369.04% | 15 | Mar 26, 2026 | |
| PPBT Purple Biotech | Maintains: Buy | $34 → $30 | $4.20 | +614.29% | 15 | Mar 13, 2026 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $9 → $7 | $3.47 | +101.73% | 3 | Mar 10, 2026 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $36 → $38 | $14.32 | +165.36% | 24 | Mar 9, 2026 | |
| SANA Sana Biotechnology | Maintains: Buy | $9 → $7 | $3.27 | +114.07% | 13 | Mar 4, 2026 | |
| RCUS Arcus Biosciences | Reiterates: Buy | $32 | $25.68 | +24.61% | 8 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $49 | $16.62 | +194.83% | 22 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $1.47 | +512.24% | 1 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $47 | $31.69 | +48.34% | 3 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $19 | $2.09 | +809.09% | 13 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $15 | $10.80 | +38.89% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $5 | $2.27 | +120.26% | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.02 | +1,076.47% | 1 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $60 | $33.85 | +77.25% | 1 | Oct 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $3.84 | +498.96% | 20 | Sep 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $4.18 | +856.94% | 15 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $8 | $0.38 | +1,983.33% | 25 | Aug 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $20 | $0.93 | +2,049.84% | 10 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $36 | $9.36 | +284.62% | 9 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $560 → $280 | $7.83 | +3,475.99% | 17 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.47 | +223.89% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $2.75 | +990.91% | 7 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $18 | $2.93 | +514.33% | 15 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $183 | $2.80 | +6,421.79% | 12 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $1.58 | - | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $2.12 | - | 1 | Apr 25, 2024 |
First Tracks Biotherapeutics
Apr 28, 2026
Initiates: Buy
Price Target: $30
Current: $22.38
Upside: +34.05%
Agios Pharmaceuticals
Apr 20, 2026
Maintains: Buy
Price Target: $65 → $50
Current: $28.16
Upside: +77.56%
MiNK Therapeutics
Apr 1, 2026
Reiterates: Buy
Price Target: $35
Current: $11.61
Upside: +201.46%
AnaptysBio
Mar 30, 2026
Reiterates: Buy
Price Target: $66
Current: $66.76
Upside: -1.14%
Atossa Therapeutics
Mar 26, 2026
Maintains: Buy
Price Target: $7 → $25
Current: $5.33
Upside: +369.04%
Purple Biotech
Mar 13, 2026
Maintains: Buy
Price Target: $34 → $30
Current: $4.20
Upside: +614.29%
SAB Biotherapeutics
Mar 10, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.47
Upside: +101.73%
Olema Pharmaceuticals
Mar 9, 2026
Maintains: Buy
Price Target: $36 → $38
Current: $14.32
Upside: +165.36%
Sana Biotechnology
Mar 4, 2026
Maintains: Buy
Price Target: $9 → $7
Current: $3.27
Upside: +114.07%
Arcus Biosciences
Mar 2, 2026
Reiterates: Buy
Price Target: $32
Current: $25.68
Upside: +24.61%
Feb 26, 2026
Maintains: Buy
Price Target: $47 → $49
Current: $16.62
Upside: +194.83%
Feb 17, 2026
Initiates: Buy
Price Target: $9
Current: $1.47
Upside: +512.24%
Dec 19, 2025
Maintains: Buy
Price Target: $36 → $47
Current: $31.69
Upside: +48.34%
Nov 25, 2025
Reiterates: Buy
Price Target: $19
Current: $2.09
Upside: +809.09%
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $15
Current: $10.80
Upside: +38.89%
Nov 6, 2025
Maintains: Buy
Price Target: $4 → $5
Current: $2.27
Upside: +120.26%
Oct 14, 2025
Initiates: Buy
Price Target: $12
Current: $1.02
Upside: +1,076.47%
Oct 6, 2025
Assumes: Buy
Price Target: $60
Current: $33.85
Upside: +77.25%
Sep 10, 2025
Reiterates: Buy
Price Target: $23
Current: $3.84
Upside: +498.96%
Aug 27, 2025
Maintains: Buy
Price Target: $32 → $40
Current: $4.18
Upside: +856.94%
Aug 11, 2025
Maintains: Buy
Price Target: $12 → $8
Current: $0.38
Upside: +1,983.33%
Jul 7, 2025
Maintains: Buy
Price Target: $40 → $20
Current: $0.93
Upside: +2,049.84%
Jul 1, 2025
Reiterates: Buy
Price Target: $36
Current: $9.36
Upside: +284.62%
Apr 16, 2025
Maintains: Buy
Price Target: $560 → $280
Current: $7.83
Upside: +3,475.99%
Apr 1, 2025
Reiterates: Buy
Price Target: $8
Current: $2.47
Upside: +223.89%
Mar 31, 2025
Reiterates: Buy
Price Target: $30
Current: $2.75
Upside: +990.91%
Mar 27, 2025
Reiterates: Buy
Price Target: $18
Current: $2.93
Upside: +514.33%
Mar 26, 2025
Reiterates: Buy
Price Target: $183
Current: $2.80
Upside: +6,421.79%
Mar 12, 2025
Reiterates: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $2.12
Upside: -